HDAC9 and lung carcinoma: Another study emphasized the active inhibitory role of HDAC and ERK signaling cascades in restricting MHC II expression in lung cancer cells, and suggested that the combinatorial blockade of these pathways may engender new responses to checkpoint therapies [29].